Should I buy or sell Haleon stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HLN shares. View HLN analyst ratings or view top-rated stocks .

How have HLN shares performed in 2024?

Haleon's stock was trading at $8.23 on January 1st, 2024. Since then, HLN shares have decreased by 0.2% and is now trading at $8.2150. View the best growth stocks for 2024 here .

Are investors shorting Haleon?

Haleon saw a increase in short interest in March. As of March 31st, there was short interest totaling 25,360,000 shares, an increase of 21.9% from the March 15th total of 20,810,000 shares. Based on an average daily trading volume, of 5,650,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 0.6% of the company's stock are short sold. View Haleon's Short Interest .

When is Haleon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our HLN earnings forecast .

How often does Haleon pay dividends? What is the dividend yield for Haleon?

Haleon announced a semi-annual dividend on Thursday, February 29th. Shareholders of record on Friday, March 15th will be given a dividend of $0.1064 per share on Thursday, May 16th. This represents a yield of 1.8%. The ex-dividend date of this dividend is Thursday, March 14th. Read our dividend analysis for HLN .

Is Haleon a good dividend stock?

Haleon (NYSE:HLN) pays an annual dividend of $0.21 per share and currently has a dividend yield of 2.62%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLN will have a dividend payout ratio of 41.18% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for HLN .

What ETFs hold Haleon's stock?

ETFs with the largest weight of Haleon (NYSE:HLN) stock in their portfolio include VanEck Pharmaceutical ETF (PPH) , ClearBridge Focus Value ESG ETF (CFCV) and Pacer BioThreat Strategy ETF (VIRS) . Horizon Kinetics Medical ETF (MEDX) .

Who are Haleon's major shareholders?

Haleon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.18%), Norden Group LLC (0.01%), JTC Employer Solutions Trustee Ltd (0.01%), First Hawaiian Bank (0.01%), Keystone Financial Planning Inc. (0.01%) and Procyon Advisors LLC (0.00%).

How do I buy shares of Haleon?

Shares of HLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:HLN

Haleon (HLN) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free HLN Stock Alerts

$8.22

+0.08 (+0.98%)

(As of 04/19/2024 ET)

Compare

Today's Range: $8.15
▼
$8.22
50-Day Range: $8.03
▼
$8.65
52-Week Range: $7.70
▼
$9.05

Volume: 3.64 million shs
Average Volume: 5.52 million shs
Market Capitalization: $37.51 billion

P/E Ratio: 29.34
Dividend Yield: 2.56%
Price Target: N/A

Get Haleon alerts:

Haleon MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
0.55% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.70
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 8.51%
From $0.47 to $0.51 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

625th out of 911 stocks

Toilet Preparations Industry

11th out of 12 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Haleon.

2.0

Short Interest

Percentage of Shares Shorted
0.55% of the float of Haleon has been sold short.
Short Interest Ratio / Days to Cover
Haleon has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Haleon has recently increased by 21.86%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Haleon pays a meaningful dividend of 2.62%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Haleon has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Haleon is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Haleon will have a dividend payout ratio of 41.18% next year. This indicates that Haleon will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HLN.

2.6

News and Social Media Coverage

News Sentiment
Haleon has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Haleon this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for HLN on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Haleon insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 6.67% of the stock of Haleon is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Haleon are expected to grow by 8.51% in the coming year, from $0.47 to $0.51 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Haleon is 29.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of Haleon is 29.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 222.74.
Price to Earnings Growth Ratio
Haleon has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Haleon has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Haleon Stock (NYSE:HLN)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

HLN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLN Stock News Headlines

April 19, 2024 | americanbankingnews.com

Haleon (NYSE:HLN) Now Covered by HSBC

March 19, 2024 | msn.com

Stocks Making Big Moves Today

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 19, 2024 | markets.businessinsider.com

Haleon Announces Pricing And Upsize Of Secondary Offering By Pfizer At $7.85/ADS

March 18, 2024 | msn.com

Pfizer to Offload Haleon Shares Worth $2.5B

March 18, 2024 | msn.com

Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B

March 18, 2024 | msn.com

London's FTSE 100 opens higher on miners' boost

March 18, 2024 | markets.businessinsider.com

Pfizer Plans To Sell About 630 Mln Haleon Shares

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 18, 2024 | reuters.com

Consumer healthcare giant Haleon says Pfizer to cut stake to 24%

March 11, 2024 | uk.finance.yahoo.com

FTSE 100 Live 11 March: Currys bidder walks away, shares steady as Nikkei reverses on GDP surprise

March 10, 2024 | finance.yahoo.com

Income Investors Should Know That Haleon plc (LON:HLN) Goes Ex-Dividend Soon

March 3, 2024 | finance.yahoo.com

Haleon (LON:HLN) Is Increasing Its Dividend To £0.042

March 2, 2024 | finance.yahoo.com

Haleon Full Year 2023 Earnings: EPS Misses Expectations

March 1, 2024 | seekingalpha.com

Haleon plc (HLN) Q4 2023 Earnings Call Transcript

February 29, 2024 | msn.com

Sensodyne-maker Haleon jumps on share buyback, falling debt

February 29, 2024 | msn.com

Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars

February 29, 2024 | seekingalpha.com

Haleon plc 2023 Q4 - Results - Earnings Call Presentation

February 29, 2024 | bloomberg.com

Haleon Says Revenue Growth Accelerated at End of Last Year

February 28, 2024 | msn.com

Reckitt's quarterly sales disappoint after investigation into Middle East business

February 19, 2024 | finance.yahoo.com

Zoetis Inc. (ZTS)

February 14, 2024 | theglobeandmail.com

1 Pharma Stock to Buy Near 52-Week Highs

February 12, 2024 | seekingalpha.com

Haleon plc: Leveraging On Brand Investment And Debt Reduction

February 6, 2024 | finance.yahoo.com

Abreva Drops One-of-a-Kind Pair of Diamond Lips, Inspired by the Cold Sore Experience

February 2, 2024 | reuters.com

Judge certifies class action challenging ChapStick 'all natural' labels

January 16, 2024 | msn.com

GSK to sell 3.2% stake in spin-off Haleon in its third stake sale in under a year

January 16, 2024 | reuters.com

GSK to sell 3.2% stake in spin-off Haleon

See More Headlines

Receive HLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haleon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/16 Dividend: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Dividend Payable: 5/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Toilet preparations
Sub-Industry: N/A
Current Symbol: NYSE:HLN
CUSIP: N/A
CIK: 1900304
Web: www.haleon.com
Phone: 44-19-3282-2000
Fax: N/A
Employees: 25,408
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.28
Trailing P/E Ratio: 29.34
Forward P/E Ratio: 17.48
P/E Growth: 2.12
Net Income: $1.30 billion
Net Margins: 9.28%
Pretax Margin: 14.40%
Return on Equity: 12.55%
Return on Assets: 6.13%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 1.04
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: $14.05 billion
Price / Sales: 2.67
Cash Flow: $0.37 per share
Price / Cash Flow: 22.17
Book Value: $4.51 per share
Price / Book: 1.82

Miscellaneous

Outstanding Shares: 4,566,150,000
Free Float: N/A
Market Cap: $37.51 billion
Optionable: Not Optionable
Beta: 0.29

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Brian James McNamara (Age 58)
CEO & Executive Director
Comp: $4.28M
Mr. Tobias Hannes Hestler (Age 52)
CFO & Executive Director
Comp: $2.38M
Ms. Sonya Ghobrial (Age 50)
Head of Investor Relations
Mr. Bjarne Philip Tellmann (Age 57)
General Counsel
Ms. Tamara Rogers (Age 54)
Chief Marketing Officer
Ms. Mairead Nayager (Age 49)
Chief Human Resources Officer
Mr. Filippo Lanzi
President of EMEA & LatAm
Mr. Keith Choy (Age 55)
President of Asia Pacific
Ms. Lisa Paley (Age 57)
President of North America
Mr. Franck Riot (Age 56)
Chief R&D Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy Haleon Stock? HLN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Haleon plc:

Haleon plc has shown consistent growth in its stock price, trading at $8.43 recently, with a market capitalization of $38.92 billion.
The company has a diverse product portfolio, including consumer healthcare products in various regions globally, providing revenue stability.
Recent institutional investments from reputable firms like Wellington Management Group LLP and Douglas Lane & Associates LLC indicate confidence in Haleon's future prospects.
Haleon plc has a low debt-to-equity ratio of 0.53, indicating a healthy financial structure and lower risk.
The company's dividend payout ratio of 75.00% suggests a commitment to rewarding shareholders with consistent dividends.

Cons

Investors should be bearish about investing in Haleon plc for these reasons:

The stock price of Haleon plc has shown minimal growth, with fluctuations around the $8 range, potentially limiting short-term capital gains.
Despite recent institutional investments, increased competition in the consumer healthcare industry could impact Haleon's market share and profitability.
The company's P/E ratio of 30.14 suggests the stock may be overvalued compared to industry peers, posing a risk of a price correction.
Haleon plc's P/E/G ratio of 2.17 indicates a higher valuation relative to its earnings growth rate, potentially signaling an inflated stock price.
Investors should consider the company's beta of 0.30, indicating lower volatility compared to the market average, which may limit potential returns in highly volatile market conditions.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

HLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Haleon stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HLN shares.
View HLN analyst ratings or view top-rated stocks.
How have HLN shares performed in 2024?: Haleon's stock was trading at $8.23 on January 1st, 2024. Since then, HLN shares have decreased by 0.2% and is now trading at $8.2150.
View the best growth stocks for 2024 here.
Are investors shorting Haleon?: Haleon saw a increase in short interest in March. As of March 31st, there was short interest totaling 25,360,000 shares, an increase of 21.9% from the March 15th total of 20,810,000 shares. Based on an average daily trading volume, of 5,650,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 0.6% of the company's stock are short sold.
View Haleon's Short Interest.
When is Haleon's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our HLN earnings forecast.
How often does Haleon pay dividends? What is the dividend yield for Haleon?: Haleon announced a semi-annual dividend on Thursday, February 29th. Shareholders of record on Friday, March 15th will be given a dividend of $0.1064 per share on Thursday, May 16th. This represents a yield of 1.8%. The ex-dividend date of this dividend is Thursday, March 14th.
Read our dividend analysis for HLN.

Is Haleon a good dividend stock?: Haleon (NYSE:HLN) pays an annual dividend of $0.21 per share and currently has a dividend yield of 2.62%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLN will have a dividend payout ratio of 41.18% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HLN.
What ETFs hold Haleon's stock?: ETFs with the largest weight of Haleon (NYSE:HLN) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), ClearBridge Focus Value ESG ETF (CFCV) and Pacer BioThreat Strategy ETF (VIRS).Horizon Kinetics Medical ETF (MEDX).
Who are Haleon's major shareholders?: Haleon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.18%), Norden Group LLC (0.01%), JTC Employer Solutions Trustee Ltd (0.01%), First Hawaiian Bank (0.01%), Keystone Financial Planning Inc. (0.01%) and Procyon Advisors LLC (0.00%).
How do I buy shares of Haleon?: Shares of HLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Haleon (HLN) Stock Price, News & Analysis

Haleon MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Haleon Stock (NYSE:HLN)

HLN Stock Price History

HLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

Should I Buy Haleon Stock? HLN Pros and Cons Explained

Pros

Cons

HLN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™